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 1 
Introduction 
Rheumatic fever (RF) and rheumatic heart disease (RHD) are interrelated disease 
entities of historical significance that continue to afflict millions of people. Despite their 
widespread impact, these ailments have been relatively neglected by developed countries, 
most likely due to the current perception that these are diseases of distant, poor 
populations. Although now generally accepted as illnesses of developing and underserved 
countries, it was not always this way. The incidence of RF was widespread among 
American youth until the mid-20th century, when it was estimated at nearly 250,000 cases 
per year (Denny et al., 1950). The rapid economic development and hygienization of 
North America and Europe in the first half of the 20th century coincided with the near 
disappearance of RF from these societies. RF did, however, remain a serious problem in 
certain populations, most notably military recruits in the WWII era who became 
convenient and important subjects of numerous studies (Denny et al., 1950; Jones, 1944).  
With each case of RF costing the US armed forces a staggering $16,000 in 1950 
dollars (Denny et al., 1950) the middle of the 20th century saw the first of the three 
modern waves of research activity to combat RF/RHD. The second surge occurred in the 
late 20th century with a push to prevent and control RF/RHD in developing countries. 
Following a stagnation of research into RF/RHD prevention and control from the global 
agenda, we are now in the third wave in research activity (Carapetis and Zuhlke, 2011). 
Although the clinical components of RF were first described in the 1500s and RF was 
linked to carditis over 200 years ago (Seckeler and Hoke, 2011) the current era of 
globalization may finally lead us to the point of bringing effective preventive treatment or 
cure to all the world’s people.  
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Background 
Rheumatic Fever and Rheumatic Heart Disease 
Acute RF is a non-communicable disease common to many developing countries 
that occurs in up to 3% of patients subsequent to untreated tonsillopharyngeal infection 
with group A β-hemolytic streptococcus (GAS) (Hewitson and Zilla, 2010). It is 
characterized by a constellation of potential signs and symptoms of varying penetrance, 
severity, and permanence (see “Diagnosis” below). It results from a still poorly 
delineated autoimmune reaction to GAS surface M-proteins with suspected production of 
anti-M-protein antibodies that react to self-proteins in susceptible victims. While 
potential targets including cardiac myosin, laminin, and vimentin have been identified, 
the carditis of RF is actually due to activated CD4+ T-cells. Genetic susceptibilities to RF 
have been proposed including identification of certain MHC and non-MHC genotypes 
that may be more susceptible than others (Guilherme and Kalil, 2010; Guilherme et al., 
2007; Kumar and Tandon, 2013). However, research into these susceptibilities has yet to 
yield clinically relevant conclusions.  
Acute RF is a predominately pediatric condition that is rarely fatal. However, 40-
80% of acute RF patients have rheumatic carditis as part of the disease process and 90% 
of these patients develop the sequelae of chronic, progressive RHD. In developing 
countries, RHD is responsible for one-third to one-half of all cardiac admissions to 
hospitals, causes two-thirds of those suffering from it to drop out of school, and is 
difficult to treat without open-heart surgery (Hewitson and Zilla, 2010). It is important to 
note that the gold-standard preventive treatment of injection with benzathine penicillin G 
(BPG), either within 10-days of onset of infectious symptoms or prophylactically every 
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four weeks, has been recognized for over 60 years (Denny et al, 1950; Stollerman et al., 
1955). Since 75% of previous RF patients progress to recurrent acute RF at reinfection 
with GAS, prevention or prompt treatment of infection is the key to preventing RF/RHD 
from developing (Hewitson and Zilla, 2010). 
 
Diagnosis of Rheumatic Fever and Rheumatic Heart Disease 
 While rheumatic fever was recognized as a clinical entity in the 19th century, it 
took until the epidemiologic advances of the WWII era for a discussion within the 
literature to culminate in the first iteration of the Jones Criteria for the diagnosis of RF 
(Jones, 1944). These criteria have been revisited and revised from time to time by the 
American Heart Association (AHA) with the most recent revised Jones Criteria released 
22 years ago (Dajani et al., 1992). The criteria are intended for the diagnosis of an initial 
attack of RF and allow for retrospective diagnosis of RF based on exceptions to the Jones 
Criteria. As in 1992, there are no single pathognomic symptoms, signs, or laboratory tests 
to diagnose RF so a combination of these must be used, as outlined below. 
 
Guidelines for the Diagnosis of Initial Attack of Rheumatic Fever* 
(modified from Dajani et al., 1992) 
Major Manifestations 
Carditis 
Polyarthritis 
Chorea 
Erythema marginatum 
Subcutaneous nodules 
Minor Manifestations 
Arthralgia 
Fever 
Elevated acute phase reactants (ESR, CRP) 
Prolonged PR interval 
Supporting Evidence of Antecedent Group A Streptococcal Infection 
Positive throat culture or rapid streptococcal antigen test 
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Elevated or rising streptococcal antibody titre 
*If supported by evidence of preceding group A streptococcal infection, 
the presence of two major manifestations or of one major and two minor 
manifestations indicates a high probability of acute rheumatic fever. 
 
The 1992 guideline continues to be the most commonly referenced throughout the 
world, though it is not the most up-to-date. The AHA revisited the guideline in a meeting 
in 2000 but did not produce an update, though they did foreshadow the utility of 
echocardiography in diagnosing and monitoring RHD (Ferrieri, 2002). An update to the 
Jones Criteria is expected to be published later in 2014 (Kathryn Taubert, personal 
communication, April 11, 2014). The World Health Organization (WHO) produced a 
technical report in 2004 that included RF and RHD diagnostic criteria based on the Jones 
Criteria (Bisno et al., 2004) and this was subsequently reaffirmed by the World Heart 
Federation (WHF) as the international standard for diagnosis (WHF, 2008).  
It is important to note the distinction between acute RF and RHD, a chronic and 
often insidious non-communicable disease. As previously noted, RF is rarely acutely 
fatal. In fact, apart from the potential development of RHD, acute RF is otherwise 
clinically benign, albeit somewhat disturbing to patients and caregivers. Unfortunately, 
RHD is chronic, progressing in a step-wise fashion with subsequent bouts of RF. It was 
recognized decades ago and included in the initial Jones Criteria (Jones, 1944). Since that 
time, its impact has lessened in the developed world while persisting in many low and 
middle-income countries throughout the developing world.  
Acute rheumatic carditis and chronic RHD were classically diagnosed clinically 
with identification of an enlarged heart, significant murmur, pericarditis, or congestive 
heart failure as diagnostic indicators (Jones, 1944). Because each of these entities occurs 
on a spectrum of clinical appearance and severity, one can see how their use as 
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diagnostics could vary widely between populations and providers. As diagnostics change, 
echocardiography has been recognized as the most sensitive and specific tool for RHD 
diagnosis (Ferrieri, 2002). RHD is known to occur in any of the four major heart valves, 
disrupting blood flow through the heart’s chambers and resulting in cardiac dysfunction 
of varying degrees. Most apparent RHD occurs in the mitral valve followed by the aortic 
valve in a smaller but significant number of cases. Disease of the tricuspid and pulmonic 
valves is rare and much less likely to cause clinically significant disease (Kumar and 
Tandon, 2013). Recently, the WHF produced a guideline for the echocardiographic 
diagnosis of RHD that excludes the tricuspid and pulmonic valves from the diagnostic 
algorithm, simplifying identification of rheumatic lesions that would be of clinical 
importance (Remenyi et al., 2012). The utility of echocardiography in RHD diagnosis has 
been further verified in recent studies comparing echocardiographic screening to 
screening by classical auscultation. These echocardiographic screening programs have 
found rates of subclinical rheumatic carditis ten to twenty times higher than previous 
screening programs. The implications of this have yet to be fully determined as it is 
unclear whether preventive interventions to inhibit the transformation of subclinical 
rheumatic carditis to clinically apparent RHD are necessary or practical (Kumar and 
Tandon, 2013). 
 
Epidemiology and RF/RHD Awareness 
The epidemiology of RF and RHD are distinct and inherently difficult to assess. 
RF, as an acute disease, is better discussed in terms of incidence, while RHD is a disease 
best discussed in terms of prevalence. RF is a clinical diagnosis without a definitive 
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laboratory test (Jones, 1944; Dajani et al., 1992). It presents differently in all patients, can 
mimic other diseases, and can be mimicked by still others (Jones, 1944). Diagnosis is 
generally based on the Jones Criteria as discussed above (Dajani et al., 1992). RHD 
continues to be diagnosed primarily by community screening with auscultation for 
cardiac murmurs or via followup of patients diagnosed with RF. For largely practical 
reasons, echocardiography has become available only in the past decade for widespread 
use to diagnose RHD and evidence-based guidelines for its use weren’t released until 
2012 (Remenyi et al., 2012). Screening programs, largely school-based and dependent on 
the auscultation skills of healthcare providers, are unable to assess all those susceptible to 
developing RHD (McDonald et al., 2005). Even in areas with a relatively high 
prevalence, patients can present to healthcare providers and not have their condition 
recognized until far along in the disease process (Steer et al., 2006). Complicating this is 
a lack of national registers of RF/RHD patients in many countries. While some low and 
middle-income countries have adopted register-based programs for preventing and 
treating RHD, most harbor much larger populations of undiagnosed patients suffering 
from these afflictions (McDonald et al., 2005). 
RF/RHD prevalence varies significantly between global regions, within regions, 
and even within countries and has changed significantly over time (Seckeler and Hoke, 
2011). Denny et al. (1950) estimated the incidence of RF in the United States to approach 
250,000 widespread cases/year. Modern outbreaks of RF in the United States tend to be 
small, numbering at most in the dozens, and rare (Seckeler and Hoke, 2011). In contrast, 
the global incidence of RF is estimated to approach 500,000 cases with an estimated 
RHD prevalence of 15-19 million cases resulting in 233,000 deaths each year (McDonald 
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et al., 2005; Seckeler and Hoke, 2011; Wyber et al., 2013). The great majority of these 
cases occur in developing countries throughout the world and in indigenous populations 
in developed countries of the South Pacific (Seckeler and Hoke, 2011; Steer and 
Carapetis, 2009). Since these data were gathered using various methods, the true burden 
may actually be much higher (Zuhlke and Steer, 2013). Accurate epidemiologic figures 
are important not just for understanding the scale of the problems posed by RF/RHD. 
Effective secondary prevention programs (discussed below) rely on appropriate use of 
registers and accurate epidemiologic data in order to function. 
 
Primordial Prevention of RF/RHD 
 Primordial prevention of RF/RHD is thought to account for the vast majority of 
decline in the incidence and prevalence of RF/RHD throughout North America and 
Europe during the 20th century (Gordis, 2005). It requires the prevention of the 
development of risk factors for disease within the community. Examples include 
improved socioeconomic status, prevention of overcrowding, improved nutritional status, 
availability of prompt medical care, and public education about RF/RHD signs and 
symptoms (Kumar and Tandon, 2013). 
 
Antibiotics for GAS Infections/Primary Prevention of RF/RHD 
 Primary prevention of RF and RHD aims to prevent the diseases from occurring 
in the presence of risk factors for the conditions. For this discussion, this broadly means 
recognition of GAS tonsillopharyngitis and subsequent treatment with antibiotics. 
Sulfonamides were the first antibiotics found to be effective at treating GAS 
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tonsillopharyngitis and preventing RF as early as 1943. Resistance of GAS to these 
antibiotics was recognized soon thereafter along with the utility of injectable and oral 
penicillin for the treatment of GAS tonsillopharyngitis (Denny et al., 1950). The 2004 
WHO guideline for RF/RHD prevention recommends any of five separate treatment 
choices be started within 9-10 days of symptom onset. These recommendations are, in 
order of preference: a single dose of intramuscular BPG, oral penicillin V 2-4 times/day 
for 10 days, oral amoxicillin 2-3 times/day for 10 days, oral first-generation 
cephalosporins 2-3 times/day for 10 days, or oral erythromycin 4 times/day for 10 days. 
At that time, trimethoprim, sulfonamides, and tetracyclines were not recommended due to 
ineffective eradication of GAS infection (Bisno et al., 2004). Despite widespread use of 
oral penicillin and BPG, GAS continues to be fully susceptible to these medications while 
developing resistance to other classes such as macrolides, lincosamides, and 
streptogramins (Logan et al., 2012) in addition to the previously mentioned classes. 
A more promising form of primary prevention involves development of a vaccine 
for GAS that has the potential to eliminate the need for primary and secondary 
prophylaxis altogether. GAS vaccine development was initiated as early as the 1940s 
with accelerated progress in the era of molecular biology (World Health Organization, 
2004). Unfortunately, an effective GAS vaccine is far from clinical use due to the 
complexities between the many GAS strains, the potential for creating a vaccine that 
itself causes RF/RHD, as well as an industry kept apathetic by little promise of 
significant profits from the poor populations who would be the primary consumers of 
such a vaccine (Kumar and Tandon, 2013; Steer and Carapetis, 2009).  
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Antibiotics for Secondary Prevention of RF/RHD 
Secondary prevention of RF/RHD involves continuous administration of 
antibiotics to patients with a history of RF or RHD in order to prevent GAS infection, 
thereby minimizing the possibility for recurrent RF attacks (World Health Organization, 
2004). Its effective administration requires both identification of patients with RF/RHD 
and maintenance of a registry of these patients (Kumar and Tandon, 2004). Injectable 
penicillin was first shown to prevent RF/RHD in patients with GAS infection over 60 
years ago (Denny et al, 1950). In the years following this study, BPG was shown to 
prevent GAS infection in patients who had previously suffered bouts of RF/RHD 
(Stollerman and Rusoff, 1952; Stollerman et al., 1955). In addition to showing the 
efficacy of BPG at preventing GAS infection and RF/RHD, the 1955 study by Stollerman 
et al. introduced the monthly regimen of benzathine penicillin G (BPG) injections that 
continues to be the gold standard of RF/RHD prevention. In this study, Stollerman et al. 
showed that a four-weekly regimen of injection with 1,200,000 units of BPG was more 
effective than daily oral administration of 200,000 units of penicillin or 1.0 grams of 
sulfadiazine. In fact, none of the patients on the injectable BPG regimen suffered a 
recurrence of RF/RHD during the 20-month follow-up period, showing that it was 
superior to both oral regimens in the long term. These findings were a tremendous 
breakthrough in the prevention of RF/RHD in the susceptible population.  
Unfortunately, while it may be true that monthly injections of BPG proved to be 
effective in the past, more recent studies have questioned the validity of this regimen with 
the BPG that is available in today’s global market (discussed below). Nevertheless, the 
WHO continues to endorse monthly BPG injections as the first line preventive treatment 
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for RF/RHD prophylaxis. Alternative protocols include oral penicillin V twice daily, oral 
sulfonamides once daily, or oral erythromycin twice daily. These treatments must 
continue for an extended duration in most patients – into adulthood for those with mild 
disease or lifelong for those with more severe disease. The oral regimens are cumbersome 
and require dedication because patients must fast for hours before and after medication 
administration. In addition, they often cause uncomfortable gastrointestinal side effects 
(Bisno et al., 2004). Benzathine penicillin G, although not without side effects and other 
drawbacks of its own, has continued to be the most effective prevention for RF/RHD yet 
described (Wyber et al., 2013). 
 
Chemical Characteristics of Benzathine Penicillin G 
BPG was first developed in 1950 and its patent was accepted in the United States 
in 1953, though it had been in clinical use in the intervening years (Stollerman and 
Rusoff, 1952; Szabo et al., 1951; Szabo et al., 1953). Injectable penicillin initially needed 
to be administered every 48-72 hours to maintain serum levels adequate to inhibit GAS 
growth (Denny et al., 1950). With the development of BPG, a single 1,200,000 unit 
intramuscular penicillin injection would consistently produce serum levels adequate to 
inhibit GAS growth for four weeks (Stollerman and Rusoff, 1952; Stollerman et al., 
1955). Initially developed as a sparingly water-soluble salt by Wyeth Pharmaceuticals 
(Stollerman and Rusoff, 1952), it is now off-patent and is made by multiple 
manufacturers. It is available in a powdered formation that is stable at ambient 
temperatures or in a suspension that must be refrigerated (Stollerman and Rusoff, 1952; 
Wyber et al., 2013).  
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Thirty years after the pioneering studies on BPG use to treat and prevent RF/RHD 
(Denny et al, 1950; Stollerman and Rusoff, 1952; Stollerman et al., 1955), Ginsburt et al. 
(1982) reported that serum levels of BPG four weeks after injection were very low or 
undetectable. A few years later, Kaplan et al. (1989) performed a study to analyze serum 
levels of injected BPG over the course of four weeks. They showed that mean serum 
levels fell below the generally accepted mean inhibitory concentration (MIC) for most 
strains of GAS (0.02µg/ml) between three and four weeks after injection. This finding is 
important because it revealed a window period during the final week of suspected 
prophylaxis during which infection with GAS might occur. Of note, BPG injection within 
ten days of onset of GAS tonsillopharyngitis can prevent RF from occurring, so 
conceivably a one-week window period would not be too long for this regimen to remain 
effective. However, in two separate studies, Lue et al. (1986 and 1996) showed that 
administration of BPG every three weeks was more effective at preventing RF than 
injecting it every four weeks. Some troubling issues arise as a result of these studies. 
First, that prophylactic regimes consisting of 1,200,000 units of BPG injected every four 
weeks are not adequate. Worryingly, the three-week regimes used by Lue et al. were not 
completely effective at preventing RF either. Logically, then, it was important to test two-
week regimens, different brands, and higher doses of BPG injection. 
Kassem et al. (1996) showed that injection of BPG every two weeks was more 
effective at preventing RF than every four weeks. In addition, their study demonstrated 
that different brands of BPG have unique pharmacokinetics, despite equivalent doses of 
the medication in the vial. Currie et al. (1994) performed a study of the pharmacokinetics 
of increased doses of BPG. Assuming the minimum protective penicillin concentration to 
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be 0.25µg/ml, they found that significantly more subjects retained protective levels of 
penicillin after two, three, and four weeks when receiving 1,800,000 units of BPG. Serum 
penicillin levels after two, three, and four weeks were higher still in those injected with 
2,400,000 units of BPG. Of note, only injection of 2,400,000 units provided protective 
levels in 100% of patients after two and three weeks. These findings led Currie and 
Kaplan (1996) to question the validity of the recommended dosing regimen of BPG. 
More recently, Broderick et al. (2011) showed that injection of 1,200,000 units of BPG 
consistently results in penicillin levels that fall below protective levels after just two 
weeks. Clearly, none of these recent studies on the subject indicate promising trends in 
the quality of available BPG. 
These findings are troubling because they show disheartening inconsistencies in 
the quality of BPG available since the 1970’s. Whereas, a four-weekly injection regimen 
of 1,200,000 units once produced adequate GAS prophylaxis throughout the treatment 
period (Stollerman and Rusoff, 1952; Stollerman et al., 1955), more recent research 
suggests much higher dosing or more frequent intervals may be necessary to provide 
protective penicillin levels (Currie et al., 1994; Currie and Kaplan, 1996; Broderick et al., 
2011). Moreover, the inability to produce protective penicillin levels may not be the only 
concerning aspect of current formulations of BPG (Wyber et al., 2013). 
 
Penicillin Reactions 
 While penicillin is a potential allergen, fear of serious allergic reactions to 
penicillin is far greater than the true risk of those reactions (Markowitz et al., 1991; 
Markowitz and Lue, 1996). In their 1955 study, Stollerman et al. monitored the 410 
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enrolled patients for reactions. While eight patients developed nonspecific, nonurticarial 
rashes during the study, only five patients were found to have penicillin hypersensitivities 
and none had fatal reactions. Despite these initial findings, fear of serious allergic 
reactions developed and has persisted despite having been addressed in the literature 
multiple times. In an 11-country study involving 1790 patients, and 32,430 injections 
through 2,736 patient-years of observation, only 57 patients (3.2%) had any type of 
allergic reaction. Of these, four had anaphylaxis (0.2% or 1.2/10,000 injections) and one 
died for a fatality incidence of 0.05% or 0.31/10,000 injections (Markowitz et al., 1991). 
Furthermore, the WHO (Bisno et al., 2004) reports that most cases of anaphylaxis are 
reported in patients who have severe RHD with poor cardiac function. They add that 
these patients are more susceptible to life-threatening vasovagal reactions that may be 
retrospectively misdiagnosed as anaphylaxis. Despite these low numbers and availability 
of skin testing that can identify essentially 100% of true penicillin allergies, fear of 
anaphylaxis persists (Markowitz and Lue, 1996). Skin testing of all newly diagnosed 
RF/RHD patients for penicillin allergy has been suggested (Markowitz and Lue, 1996), 
and while the WHO does not recommend it for all patients, they acknowledge its utility 
as an acceptable and generally accurate method to determine risk of immediate penicillin 
reaction (Bisno et al., 2004). 
 
Rheumatic Fever/Rheumatic Heart Disease Prevention Guidelines 
Rheumatic fever and RHD are complex diseases affecting diverse populations 
living in various political and economic climates throughout the world. As described 
above, they present and can be prevented and treated in a myriad of different ways. 
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Because of this, there are numerous guidelines covering RF/RHD diagnosis, prevention, 
and treatment available to clinicians. However, the WHO guideline (Bisno et al., 2004) is 
the standard reference document that is pertinent worldwide. This guideline continues to 
recommend injection of 1,200,000 units of BPG every four weeks as a starting point for 
RF/RHD prophylaxis (Bisno et al., 2004). However, this is simply a starting point 
suggested by the WHO that clinicians can use as guidance – in truth, each patient is 
unique. If a patient is still suffering from breakthrough GAS infections on a three or four 
week regimen of BPG injections, their healthcare provider may increase the frequency of 
injections or inject a greater amount of BPG. A single injection of 2,400,000 units of 
BPG is the recommended treatment for syphilis infection, so this formulation is available 
to many clinicians and it is conceivable that some may perform BPG prophylaxis with it. 
Of course, these conceptions are only speculation at this point because there is a lack of 
knowledge about how clinicians are actually treating their patients and what guidelines 
they subscribe to. Clinical guidelines are created for the purpose of improving outcomes 
in conditions that can be diagnosed and treated in more than one way. Current adherence 
to RF/RHD prophylaxis guidelines throughout the world is not known. Additionally, 
there is anecdotal evidence of widespread BPG shortages and clinical failures in patients 
receiving treatment under the various recommended RF/RHD prophylaxis guidelines 
(Bongani Mayosi, personal communication, July 29, 2011; Edward Kaplan, personal 
communication, September 20, 2011). It is not clearly known which countries have 
experienced BPG shortages or supply of poor-quality BPG, nor are the reasons for this 
clearly understood. 
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Current Study 
Central and South America, the Caribbean, Africa, and the Asia-Pacific region 
continue to have the highest rates of RF/RHD (Seckeler and Hoke, 2011) and the current 
adherence to RF/RHD prophylaxis guidelines in these regions is not known. The current 
study seeks to examine the scope of BPG supply issues and the extent of adherence to 
current RF/RHD prophylaxis guidelines in global regions with a high prevalence of 
RF/RHD. The specific objectives are: to determine which types of provider or institution 
and which countries have an inadequate supply of BPG; to determine which types of 
provider or institution and which countries have a supply of BPG that is of poor quality; 
to compare the quality and quantity of BPG supply to importation vs. domestic 
production status; to investigate the relationship between quantitative and qualitative 
deficiencies in the BPG supply according to practice setting; and to relate the quality and 
quantity of BPG supply to practice adherence to current WHO guidelines on prophylaxis 
against RF/RHD. The overall goals of the research will be to delineate BPG supply 
issues, determine what factors contribute to poor quantity or quality of BPG supply, and 
determine if healthcare practitioners are providing BPG appropriately. 
 
Methods 
Research Design 
  A pilot study was conducted to determine current practice in the prevention of 
RF/RHD in developing countries. While the efficacy of successive BPG injections for 
secondary prophylaxis was established long ago (Stollerman et al., 1955), there are no 
known global studies on the effectiveness of this regimen. In order for a treatment to be 
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effective, it needs to be available, practical, and used appropriately. A descriptive project 
of this scale, dealing with as many developing countries as possible, was best undertaken 
by performing a global survey of healthcare providers about their clinical experiences. 
This survey attempted to address three main unanswered questions: which RF/RHD 
treatment guidelines are being followed, if following the guidelines is effective, and what 
are the barriers to effectively providing RF/RHD prophylaxis. This research attempts to 
fill one of the gaps in our knowledge of current practices in the prevention of RF/RHD. 
 
Logic model 
 
 
The following hypotheses were tested in this study: 
1. Poor quality and quantity of BPG supply will be widespread, but especially in 
those countries without a domestic supply of BPG.  
2. Specialist care (i.e., via cardiologists or infectious disease doctors) will be 
correlated with better quality and quantity of BPG supply. 
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3. Obtaining BPG from a secondary source (i.e., via UNICEF or a non-governmental 
organization (NGO)) will be correlated with better quality and quantity of BPG 
supply. 
4. Practices in urban settings will be more likely to have better quality and quantity 
of BPG supply than rural settings. 
 
Study Population/Sampling Approach 
 The survey (see Appendix 2) was designed to obtain essential information on 
quantitative and qualitative BPG supply issues in global regions that have a high burden 
of RF/RHD. It targeted healthcare providers – physicians and physician extenders – who 
perform primary and/or secondary RF/RHD prophylaxis using BPG in these global 
regions. Survey recipients were identified by scanning the WHF database of member 
health professionals for those with a clinical interest in RF/RHD in the following regions: 
Central and South America, Caribbean, Africa, and Asia-Pacific. Email addresses for 
recipients were identified and surveys with introductory emails in English, English and 
French, or English and Spanish (depending on the country of the recipient) were sent out 
in December 2011. Two additional follow-up emails were sent to non-responders in the 
first months of 2012. The survey introduction included a statement excluding providers 
who do not directly participate in RF/RHD prophylaxis. It also included a section for 
WHF-linked providers to include contact information of colleagues who also work in the 
RF/RHD field. Recipients identified in this manner were also contacted via email. The 
target sample size was 100. 
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Description of variables 
1. Clinic characteristics. Apart from the commonality of treating RF/RHD patients, 
clinics have the potential to vary widely in their characteristics. Factors that can be 
used to describe clinics include the following: 
Country refers to the country in which the clinic is located, i.e. where RF/RHD 
prophylaxis is performed. 
Designation/Title refers to the professional title of the healthcare practitioner 
filling out the survey, whether they be a specialty or primary care doctor, nurse 
practitioner, pharmacist, or otherwise. 
Organization is the entity, be it public or private, at which the BPG prophylaxis 
is performed by the clinician. 
Practice setting refers to broad characteristics of individual clinics, whether they 
are in an urban or rural setting, primary care or specialty practices, hospital-based or free-
standing clinic, and whether they are private or public. This information is important for 
examining the settings that may be predisposed to BPG supply issues. 
 
2. BPG characteristics. BPG is sold in many forms that vary in their indications, utility, 
and storage. Not all forms may be available to each clinic so factors that can be used 
to differentiate types of BPG provided to individual clinics include the following: 
 Brand name refers to the company brand under which a particular batch of BPG 
is sold. 
 Manufacturer refers to the entity that manufactured a particular batch of BPG. 
 Supplier is the entity that provides the BPG to the organization that is using it. 
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 Preparation is the state in which BPG is provided to the clinic, be it in solution 
or lyophilized into powder form. 
 Reconstitution is the process by which powdered BPG is brought back into 
solution when the product is delivered and stored in powdered form but needs to be 
injected in liquid form. 
 Diluent refers to the type of liquid that needs to be added to powdered BPG to 
bring it into solution. This can be sterile water, phosphate buffered saline, or solubilized 
lidocaine/lignocaine. 
 Dose formulations are the doses of BPG that are available to the clinic – 
typically 600,000 or 1,200,000 units (the recommended dosages for BPG prophylaxis 
depending on patient weight) or 2,400,000 units (the recommended dosage for treatment 
of syphilis). 
 Types of BPG formulations refers to solubilized BPG which can be provided 
solely in buffered saline solution, mixed with anesthetics such as lidocaine/lignocaine, or 
otherwise. 
 
3. Quantity of available BPG. Clinics may vary in both the number of patients they have 
who require BPG and their ability to procure enough of the antibiotic. Factors that 
relate the number of patients each clinic can treat to the number of patients that 
require care include the following: 
Primary prophylaxis refers to the practice of treating patients known to be 
suffering from GAS tonsillopharyngitis in order to cure the infection as well as prevent 
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the development of RF/RHD. It can be done by administering one of several different 
antibiotics, including BPG, given via injection or oral administration. 
Secondary prophylaxis refers to the practice of providing regular BPG 
injections, typically every 3-4 weeks, in order to avert all GAS infections, thereby 
preventing the infection that leads to the development of RF/RHD. 
External organization refers to a secondary supplier of BPG that procures the 
product on behalf of individual clinics and distributes it to them. Examples include 
UNICEF and a number of NGOs. 
Antibiotic alternatives refer to a number of different antibiotics that can be used 
to treat GAS tonsillopharyngitis. It should be noted that they are all suitable alternatives 
for primary prophylaxis in certain circumstances while only some are suitable for 
secondary prophylaxis. 
 
4. Quality of available BPG. BPG is produced by numerous manufacturers in countries 
throughout the world. Some companies make and sell BPG under their brand name 
while others buy from a primary manufacturer and redistribute the BPG under their 
own brand name. Because of the varying manufacturers, processes, and quality 
control standards, BPG from different companies (or even from different 
manufacturers but sold under the same brand name) can vary widely in quality. 
Factors that pertain to the quality of BPG supplied to each institution include the 
following: 
Quality of BPG supply is a purely subjective measure based on the clinician’s 
opinion of the current BPG stock in use. 
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Breakthrough rheumatic fever occurs when GAS infection and subsequent RF 
ensues despite a patient appropriately taking BPG secondary prophylaxis. 
Rash is the dermatologic condition that is the most common side effect of BPG 
prophylaxis. It is anecdotally reported to occur more often with poor-quality batches of 
BPG. 
Anaphylaxis is a serious allergic reaction that occurs rapidly and has the potential 
to cause death.  
Skin testing can be performed on patients to determine if they’re allergic to 
penicillin before injecting them with BPG. 
 
5. National and international guidelines. A number of international organizations have 
developed RF/RHD prevention guidelines in order to promote and ensure access to 
appropriate preventive treatment. Factors related to guideline use include the 
following: 
Structured national programs for RF/RHD control have been established in a 
number of countries to assist clinicians in tracking and treating patients. 
National RF/RHD registries are lists of RF/RHD patients that are tracked in 
order to ensure continued treatment when they move from one area to another. 
Recurrent RF is a condition where a patient who previously had RF gets it again. 
It should be noted that those that have previously developed RF are significantly more 
likely to develop it again if they are reinfected with GAS. When recurrent RF occurs 
while the patient is undergoing appropriate BPG prophylaxis, it is called breakthrough 
RF. 
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Scheduling refers to the timetable through which patients undergo secondary 
prophylaxis with BPG. The WHO recommends injecting BPG every four weeks for most 
patients but every three weeks for patients at high risk of recurrent RF or who suffer from 
breakthrough RF on every four-week injections. 
 
Survey Development 
 Data were collected through a web-based survey that was modified from a 
previous version developed by the WHF and available for download on the RHDnet 
website (http://www.world-heart-federation.org/what-we-do/rheumatic-heart-disease-
network/). The survey included six sections. The first section asked for identifying 
information to classify the respondent by country and clinical setting in addition to 
contact information to report the compiled results. The second asked for information 
about the most common brands of BPG currently in use including the brand names, 
manufacturer, manufacturer’s address, supplier, expiration date, preparation method, 
reconstituted volume, type of diluent, available dose formulations, and types of 
formulations. Respondents were also prompted for general comments about the BPG 
currently being used. The third section asked for information about the quantity of BPG 
used at the practitioner’s clinic including the approximate number of RF/RHD patients 
served and the approximate number of RF/RHD patients they’re able to treat. They were 
also asked about any brand changes and the reasons why brands were chosen, secondary 
sourcing of BPG, antibiotic alternatives, as well as their general comments. The fourth 
queried respondents about the quality of the BPG supply including their general opinion 
about the quality of BPG used and any difficulties encountered including difficulty 
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reconstituting BPG, difficulty drawing BPG into syringes, evidence of breakthrough 
rheumatic fever, rash, anaphylaxis and death, skin testing for penicillin allergy, as well as 
space for general comments. The fifth section probed for adherence to national and 
international guidelines on the prevention of RF/RHD. Specifically, the survey included 
questions about the presence of a structured national program for RF/RHD control, a 
national RF/RHD registry, and whether the practitioner reports into it. This section also 
asked about guidelines used and BPG injection schedules followed. Finally, the sixth 
section provided space for the practitioner to recommend other healthcare professionals 
to contact. Once developed, the survey was professionally translated into French and 
Spanish (see Appendix 2). 
 
Data Analysis 
Data were compiled and analyzed using IBM SPSS Statistics 20 (IBM Corp., 
2011). Descriptive statistics such as counts and percentages were produced for discrete 
variables. None of the data is of a continuous nature so descriptive statistics such as 
means were not produced. Relationships between variables were examined through a 
bivariate analysis comparing clinic characteristics and other independent variables to 
dependent variables of BPG product supply and clinical practice. Chi-Square and Fisher’s 
exact tests (depending on sample size) were used to test for statistical significance. 
 
Human subjects 
 All data were provided to the investigator directly by survey respondents and then 
broken down by country of practice to remove identifying information and preserve 
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confidentiality. The survey did not collect any specific patient health data or sensitive 
information about physician practices. Only the research staff had access to the data, 
which were stored on an encrypted, password-protected computer. Because of the limited 
data collected and safeguards in place, there was very little risk to subjects. Prior to data 
collection, the study was determined by the University of Connecticut Health Center 
Institutional Review Board not to be human subjects research. 
 
Results 
Response data 
As is frequently the case with web-based surveys, the response rate was low. 
Eighty-nine recipients were identified in the WHF database for Africa and one additional 
referral was made by recipients. Eighty-one recipients were identified in the WHF 
database for the Asia-Pacific region and eight additional referrals were made. One-
hundred-twenty-nine recipients were identified in the WHF database in Central and South 
America and two additional referrals were made. Twenty-three recipients were identified 
in the WHF database for the Caribbean region. A total of 333 recipients received 
introductory emails and surveys to return. Although 39 questionnaires were returned, not 
all were completely filled out so percentages were calculated based on the total number 
of responses to each question. This resulted in apparent discrepancies between the 
number of responses to a question and the percentage of responses that this represents.
 The 39 completed surveys represent a gross 11.7% response rate. Twenty other 
email respondents self-identified as ineligible for the study. Five of these responses gave 
qualitative data about RF/RHD and BPG availability in their area but did not fill out the 
 25 
survey. The net response rate was 12.4%. Please see Appendix 1 for all tables and figures 
describing the respondents and the results. 
Eighteen respondents were from the Asia-Pacific region representing 46% of the 
total. Fifteen (39%) were from African countries while six (15%) were from Central and 
South America (Table 1). By country, India had by far the largest number of responses at 
ten, representing 25.6% of the total. Three responses were from Brazil. There were two 
each from Cameroon, Egypt, Ethiopia, and Malaysia. One response each was gathered 
from Bangladesh, China, Ghana, Guatemala, Honduras, Kenya, Lebanon, Mozambique, 
Nepal, Nigeria, Pakistan, Peru, Rwanda, South Africa, Tanzania, The Sudan, Uganda, 
and Yemen (Table 2). Demographic data could not be gathered from those who did not 
reply. 
 
Supply Quantity Data 
Sources of BPG varied widely. Over half of respondents (57%) reported obtaining 
BPG from a domestic source. For those respondents who had an international source, 
eight (53%) sourced from China, four (27%) from India, and three (20%) from Austria 
(Figure 1). Only one survey respondent reported no availability of BPG. The great 
majority (97%) reported access to at least some BPG. Six respondents (19%) reported 
that they require patients to supply some or all of their own BPG from a 
pharmacist/chemist for administration at the clinic/hospital, while the remainder reported 
providing BPG to their patients. Sixteen respondents (42%) reported issues maintaining 
their BPG supply. Sixteen respondents (42%) reported changing BPG brands in the 
previous two years (Table 3). Of those that reported changing brands in the previous two 
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years, 85% did so because of availability, 31% due to affordability, and 8% due to 
quality. Of note, no respondents reported changing due to packaging, storage 
requirements, or because an outside organization determined the need to change (Figure 
2).  
Six factors were assessed for their influence on choice of BPG brand. Seventy-six 
percent of respondents reported that their choice was influenced by availability of a 
particular brand, 53% by affordability, 34% by quality, 5% by packaging, and 11% by 
storage requirements. Only 13% had their choice of BPG determined by an external 
organization (Figure 3). Similarly, five respondents (14%) reported that their supply of 
BPG is dependent on an external organization. To further assess the adequacy of supply 
quantity, respondents were asked how many of their patients they would be able to treat 
according to the recommended prophylaxis guidelines. Sixty-five percent said that their 
supply is adequate to treat 100% of their patients appropriately. However, one respondent 
noted an ability to treat 87.5% of their patients appropriately, one reported 75%, another 
67%, four replied an ability to treat 50% of their patients appropriately, and one noted a 
supply adequate to treat only 10% of their patients appropriately. Four indicated that they 
were unable to treat any of their patients with the recommended prophylaxis schedule 
(Figure 4). Thirty-two percent of respondents noted no access to oral penicillin, the 
second line RF/RHD preventive medication according to WHO guidelines (Table 3).  
In spite of documented issues with the supply of BPG and other treatments, this 
analysis revealed that adherence to guidelines was unrelated to supply quantity factors 
including issues maintaining supply (2-sided Pearson χ2=0.44, p=0.507) or a brand 
change in the previous two years (2-sided Pearson χ2=0.873, p=0.35). In addition, 
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secondary sourcing was unrelated to supply quantity factors such as issues maintaining 
supply (2-sided Pearson χ2=0.972, p=0.324) or a brand change in the previous two years 
(2-sided Pearson χ2=0.003, p=0.954). 
 
Supply Quality Data 
Respondents were asked to rate the quality of their BPG supply. Nine percent 
reported that their supply was excellent, 34% rated it very good, 46% rated it good, 9% 
rated it fair, and 3% rated it of poor quality (Figure 5). Respondents were then asked 
about specific issues with BPG quality. Six percent reported difficulty reconstituting BPG 
prior to injection. Twenty-six percent reported difficulty drawing reconstituted BPG into 
syringes for injection. Eleven percent reported that they have had patients who 
experienced breakthrough RF despite being on an appropriate prophylaxis regimen. 
Three percent reported that rash is a common side effect of BPG administration. Twenty-
six percent reported that they have had patients experience anaphylaxis while on the 
current BPG used in their clinic/hospital. Twenty-one percent of respondents reported 
that they have had one or more patients die due to anaphylaxis (Table 4). A follow-up 
question assessed changes in clinical practice following anaphylaxis to BPG. Five 
respondents reported no change to their clinical practice, one stopped using BPG, two 
changed brands of BPG, and three switched some patients to an oral antibiotic. 
African countries were more likely to order their BPG from China with some 
respondents reporting domestic production. Whereas, most respondents in the Asia-
Pacific region reported domestic production (mostly from India) and most from Central 
and South America reported domestic production as well (Table 5) (2-sided Pearson 
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χ2=14.9, p=0.021). The respondents’ ratings of BPG quality were not related to country 
of production (2-sided Pearson χ2=7.6, p=0.816). 
 Sixty-percent of respondents reported performing penicillin allergy skin testing. 
However, the rate of skin testing was unrelated to whether a provider reported 
anaphylaxis at their site (Fisher’s Exact Test p=0.26) or deaths from anaphylaxis 
(Fisher’s Exact Test p=0.68).  
Whether or not a provider had a domestic or international supplier was unrelated 
to their patients’ tendency to suffer breakthrough RF (2-sided Pearson χ2=1.2, p=0.273), 
rash (2-sided Pearson χ2=1.373, p=0.241), or anaphylaxis (2-sided Pearson χ2=0.001, 
p=0.982). Furthermore, domestic vs. international supplier was completely unrelated to 
providers’ perception of the quality of their BPG (Figure 7) (2-sided Pearson χ2=4.51, 
p=0.342). 
Five respondents (14%) reported that they receive their BPG from a secondary 
source (Table 3). Statistical analysis revealed that whether or not a secondary source was 
used was unrelated to BPG quality factors including perceived quality (2-sided Pearson 
χ2=7.225, p=0.124), breakthrough RF (2-sided Pearson χ2=0.455, p=0.5), rash (2-sided 
Pearson χ2=0.172, p=0.679), or anaphylaxis (2-sided Pearson χ2=1.395, p=0.238). 
 
Data on Guideline Usage 
Data were gathered on which clinical practice guidelines for RF/RHD treatment 
and prophylaxis are used by clinicians. Seventeen respondents reported exclusive use of 
the WHO guideline, two used the AHA guideline (Gerber et al., 2009), one used the 
WHF guideline, one used the guideline produced by The Cardiac Society of Australia and 
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New Zealand, one used that produced by the Pakistan Cardiac Society, two used that 
produced by the Brazilian Society of Cardiology, and eleven referenced multiple 
guidelines. Four respondents reported following no specific guideline. Only 32% of 
respondents reported using BPG dosages and schedules recommended by the WHO 
(Bisno et al., 2004). This analysis revealed that adherence to guidelines was unrelated to 
BPG quality factors including perceived quality (2-sided Pearson χ2=1.645, p=0.801), 
breakthrough RF (2-sided Pearson χ2=0.185, p=0.667), or anaphylaxis (2-sided Pearson 
χ2=0.491, p=0.484). 
 
Discussion 
The current study was a descriptive, pilot study that sought to examine the scope 
of BPG supply issues and the extent of adherence to current RF/RHD prophylaxis 
guidelines in global regions with a high prevalence of RF/RHD. The specific objectives 
were: to determine which types of provider or institution and which countries have an 
inadequate supply of BPG; to determine which types of provider or institution and which 
countries have a supply of BPG that is of poor quality; to compare the quality and 
quantity of BPG supply to importation vs. domestic production status; to investigate 
quantitative and qualitative deficiencies in the BPG supply to practice setting; and to 
relate the quality and quantity of BPG supply to practice adherence to current WHO 
guidelines on prophylaxis against RF/RHD. The overall goals of the research were to 
delineate BPG supply issues, determine what factors contribute to poor quantity or 
quality of BPG supply, and determine if healthcare practitioners are providing BPG 
appropriately.  
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Limitations 
This study had several limitations inherent to survey-based studies, particularly 
those conducted by mail or email without personal contact. These limitations include low 
response rates and incomplete data collection because there is little control over who 
replies to survey requests or ability to follow-up on missing data. The number of 
responses was quite low. The snowball question at the end of the survey was meant to 
increase the study population. However, the effectiveness of this method is variable and 
unproven and was not of great benefit to this study. Potential study subjects were 
identified in the WHF database, a database which lacked demographic information on 
many of recipients of the survey. It is possible that many of those who received the 
survey deselected themselves without responding to the email requests. Furthermore, it is 
unlikely that the database contained contact information on many of the RF/RHD 
providers throughout the world, though it is the most complete database known to the 
author. These limitations may have led to selection bias in the research process. 
Survey responders may have been more likely to have a stronger emotional 
connection with RF/RHD and BPG supply issues, perhaps because of a lack of supply or 
poor supply. On the other hand, those clinicians with the poorest supply may be in areas 
with no internet connection and thus an inability to receive or fill out the survey. The 
sampling method itself is of questionable completeness as the original study subjects 
must have voluntarily contacted the WHF, indicated an interest in RF/RHD, and agreed 
to have their name and contact information added to the database of healthcare 
professionals. These limitations may have led to both selection and detection bias in the 
research process. 
 31 
The survey was a cross-sectional study of BPG supply and use at one point in 
time. The survey was performed as a pilot study that was meant to provide descriptive 
statistics and a launching pad for further research. Because a global survey of BPG 
availability and RF/RHD guideline use has not been performed before, there were no 
similar studies to compare the results to.  
 Finally, due to the limited number of responses, several statistical tests could not 
be performed while others produced data that would not have been helpful in addressing 
the objectives. These include analyzing BPG supply quantity and quality between types 
of provider, practice setting, countries, and regions. Despite these limitations, the results 
of the study are suggestive and worthy of further investigation. 
 
Objective 1: Determine which types of provider or institution and which countries have 
an inadequate supply of BPG 
Hypothesis 1 stated that poor quantity of supply would be widespread. 
Unfortunately, due to the erratic response rate, statistical analyses for patterns of poor 
supply were inconclusive. However, this survey confirmed that BPG supply shortages 
occur and many providers are unable to provide the recommended prophylaxis to their 
patients (see Table 3, Figure 2, and Figure 4). In addition to the tallied survey results, the 
principle investigator received two emails from respondents with ‘regrets’ that they 
couldn’t fill out the questionnaire due to lack of access to any BPG. Thus, there were 
actually three out of 41 email responders (7%) who reported no access to BPG (two from 
India and one from Lebanon), even though only one of the three filled out the survey. A 
review of the available literature about availability of essential medicines revealed an 
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article which showed availability of BPG at both public and private facilities in India was 
extremely poor (Kotwani, 2013). In light of the current analysis, these results are not 
particularly surprising. 
 
Objective 2: Determine which types of provider or institution and which countries have a 
supply of BPG that is of poor quality 
Hypothesis 1 stated that poor quality of supply would be widespread. This survey 
assessed BPG quality from two directions. First, providers were asked to assess the 
quality of their supply. A strong majority of providers rated their BPG of good, very 
good, or excellent quality (Figure 5). However, these results do not appear to agree with 
the providers’ responses to questions directed toward specific BPG quality issues (Table 
4). For example, many providers reported difficulties with BPG preparation and there 
were a fair number who reported breakthrough cases of RF among their patients while on 
BPG prophylaxis. Most importantly, an alarming number of providers reported cases of 
anaphylaxis due to BPG with nearly as many reporting deaths in these patients. These last 
two points warrant further discussion because a single case of anaphylaxis has the 
potential to destroy a secondary prophylaxis program (Markowitz et al., 1991). 
Anaphylaxis is a serious allergic reaction that can be fatal if untreated. However, accurate 
recognition of the symptoms followed by prompt treatment dramatically improves the 
chances of survival. WHO guidelines don’t explicitly recommend that all patients be 
tested for penicillin allergy (Bisno et al., 2004) and only 60% of respondents reported 
testing their patients despite the essentially 100% accuracy that the test can pick up 
patients who may suffer anaphylaxis from BPG injection (Markowitz and Lue, 1996). 
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The reasons for this are unclear. It may be due to availability or affordability of testing 
supplies. It may also be due to clinician preference not to test, a lack of testing of all 
patients, or imprecise testing methods since this study showed that penicillin testing was 
unrelated to whether or not patients were suffering anaphylaxis. 
 
Objective 3: Compare the quality and quantity of BPG supply to importation vs. domestic 
production status 
Hypothesis 1 stated that poor quality and quantity of supply would be worst in 
those countries without a domestic supply of BPG. This investigation showed that 
domestic vs. international supplier was unrelated to various indicators of BPG quality. 
Specifically, it was unrelated to providers’ perception of quality and the tendency of the 
providers’ patients to suffer breakthrough RF, rashes, or anaphylaxis. 
 
Objective 4: Investigate the relationship between quantitative and qualitative deficiencies 
in the BPG supply according to practice setting 
Hypothesis 2 stated that specialist care would be correlated with better quality and 
quantity of BPG supply and hypothesis 4 stated that practices in urban settings will be 
more likely to have better quality and quantity of BPG supply than rural settings. 
However, virtually all respondents self-identified as specialists in an urban hospital, 
making it impossible to draw conclusions about BPG supply patterns in relation to 
specialty or practice setting. The lack of participation from clinicians practicing in non-
hospital settings and in rural areas leave it an open question about BPG practices in these 
settings. 
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Hypothesis 3 stated that obtaining BPG from a secondary source would be 
correlated with better quality and quantity of BPG supply. Five respondents reported that 
they receive their BPG from a secondary source. Statistical analysis revealed that whether 
or not a secondary source was used was unrelated to BPG quality factors including 
perceived quality, breakthrough RF, rash, or anaphylaxis. Furthermore, secondary 
sourcing was unrelated to supply quantity factors including issues maintaining supply or 
a brand change in the previous two years. 
 
Objective 5: Relate the quality and quantity of BPG supply to practice adherence to 
current WHO guidelines on prophylaxis against RF/RHD 
Only 32% of respondents reported using BPG dosages and schedules described in 
the WHO guideline (Bisno et al., 2004). While many of the respondents reported using 
other guidelines, these tend to mirror the WHO guideline with few minor differences. It is 
surprising that so many respondents reported different dosages or dosing schedules than 
would be expected and it was hoped that this survey would reveal reasons for the 
discrepancies. However, the analysis revealed that adherence to WHO guidelines was 
unrelated to BPG quality factors including perceived quality, breakthrough RF, or 
anaphylaxis. Unexpectedly, adherence was unrelated to supply quantity factors including 
issues maintaining supply or a brand change in the previous two years. Thus, it is difficult 
to draw conclusions as to why practice patterns are different than expected. 
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Implications 
The overall goals of the study were to delineate BPG supply issues, determine 
what factors contribute to poor quantity or quality of BPG supply, and determine if 
healthcare practitioners are providing BPG appropriately. Very little is known about the 
topics covered in the survey so this is a unique study that has the potential to provide the 
global community interested in RF/RHD with insight into the issues surrounding 
appropriate RF/RHD prophylaxis. RF/RHD prevention guidelines are under constant 
review as there have been several changes in the field in the past few years – better 
detection techniques have led to improved and earlier diagnosis that has increased the 
observed disease burden significantly in some countries (Kumar and Tandon, 2013), 
while resistance to some antibiotics other than BPG has led to changes in prophylaxis 
protocols over the years (Bisno et al., 2004). In addition, there has been a push in recent 
years to determine what should be the research priorities in the field of RF/RHD 
prevention and treatment (Carapetis and Zuhlke, 2011; Wyber et al., 2013).  
This project did not narrow the prospects for further research. By putting numbers 
on the anecdotes of poor BPG supply it shined light on the problem while also leaving us 
with more questions than answers. It is hoped that this pilot study will act as a nidus for 
further research to more fully describe where supplies are poor and the reasons for the 
quality of supply. Because of the internet-based survey methodology, the results were 
limited in their ability to describe the problems of BPG supply and RF/RHD treatment 
and prevention. More focused country-by-country in-person or telephone interviews 
could be used to garner a more accurate and detailed description of the problems each 
provider and each country faces. Many contacts were identified in the WHF database for 
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practical reasons. However, the database was incomplete and out of date, making it a less 
than ideal source for finding practitioners who treat RF/RHD throughout the world. That 
said, there is no other known similar database in which to find contacts and a more 
rigorous identification of potential survey participants was beyond the scope of this 
project given the time and resource constraints. Therein lies the opportunity for a follow-
up study with time and resources to locate and contact a larger sample of practitioners 
and perform a more qualitative, interview-based study, as is commonly done after pilot 
projects such as this.  
As a pilot study that provided limited information on reasons for poor BPG 
supply, there is little in this work to support policy implications at this point. Research 
leading to more rigorous identification of factors that result in poor BPG supplies is the 
logical next step in the process and will be much more valuable for determining relevant 
public policy changes to improve supplies throughout the world.  
RF and RHD were major problems worldwide until the 20th century, the century 
in which RF and RHD were nearly eradicated from developed countries (Jones, 1944; 
Seckeler and Hoke, 2011). However, as we settle into the 21st century, RF and RHD 
continue to plague developing countries and indigenous populations in some developed 
countries as well (Seckeler and Hoke, 2011; Zuhlke and Steer, 2013). Given the 
socioeconomic characteristics of the populations at high risk for development of 
RF/RHD, treatment regimens must be inexpensive, effective, and easily adhered to. Until 
this study, there was much speculation and little data about the global supply of BPG. It 
is hoped that the results of this work will shine light onto the erratic nature of the global 
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BPG supply so that we can provide this essential medicine in high quality to all those 
who need it. 
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Appendix 1: Tables and Figures 
 
Table 1. Number and Percent of Responses by Region 
  Number Percent 
Africa 15 39% 
Asia-Pacific 18 46% 
Central & South America 6 15% 
 
 
Table 2. Number and Percent of Responses per Country 
Country Number Percent 
India 10 25.6% 
Brazil 3 7.7% 
Cameroon, Egypt, 
Ethiopia, Malaysia 
2 each 5.1% each 
Bangladesh, China, 
Ghana, Guatemala, 
Honduras, Kenya, 
Lebanon, Mozambique, 
Nepal, Nigeria, 
Pakistan, Peru, 
Rwanda, South Africa, 
Tanzania, The Sudan, 
Uganda, Yemen 
1 each 2.6% each 
Total 39 100.0% 
 
 
Table 3. Percent of Respondents in Agreement to Statements Relating to 
Supply Criteria 
Statement 
Percent in 
agreement 
Any availability of BPG 97% 
Patients required to supply their own BPG from a 
pharmacy/chemist in part or for all doses 
19% 
Any issues maintaining BPG supply 42% 
BPG brand change within the past two years 43% 
BPG supply is dependent on an external organization 14% 
Access to oral penicillin 68% 
 
 
 42 
Table 4. Percent of Respondents Reporting Specific Issues with BPG 
Quality 
BPG quality issue Percent 
Difficulty reconstituting BPG 6% 
Difficulty drawing BPG into syringe 26% 
One or more patients have had breakthrough 
RF while on BPG prophylaxis 11% 
Rash is a common side effect of BPG 3% 
One or more of their patients have had 
anaphylaxis on current brand of BPG 26% 
One or more of their patients have died due 
to anaphylaxis from BPG 21% 
 
 
Table 5. Location of BPG Production for Each Region (n=35)*  
  State that produces BPG for organization 
Region Domestic production China India Austria 
Africa 5 8 1 1 
Asia-Pacific 12 0 2 2 
Central & South America 3 0 1 0 
*2-sided Pearson χ2=14.9 (p=0.021)    
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Appendix 2: Introductory Emails and Surveys 
 
English-Only Introductory Email 
 
Dear Dr. __________, 
 
You are being contacted because we, at the World Heart Federation, have identified you 
as having a clinical interest in rheumatic fever or rheumatic heart disease. You have been 
chosen to participate in an important survey-based study that seeks to recognize treatment 
protocols currently in use by clinicians who perform primary or secondary prophylaxis on 
rheumatic fever or rheumatic heart disease patients. We are attempting to define and 
assess quantitative and qualitative benzathine penicillin G supply issues in global regions 
with a high burden of rheumatic fever and rheumatic heart disease. You know how 
important it is for your RHD patients to receive appropriate care and we have had reports 
of penicillin shortages and poor quality penicillin. The attached survey should take 
approximately 15-30 minutes to complete. You may be the only survey respondent in 
your country so don't let your country’s voice go unheard! Individual results will be held 
confidential and compiled results will be distributed to all survey respondents. Your 
individual participation in this survey is extremely important and the validity of the study 
depends on adequate numbers of respondents - every response counts. If you have any 
questions about the study or the validity of this email, please don't hesitate to contact me 
by hitting 'reply' or writing to Stephen.Marko@worldheart.org. You may also call me at 
+1 802-324-5803 (please note that my time zone is GMT minus five hours). I look 
forward to your reply. 
 
Thank you, 
Stephen Marko 
World Heart Federation 
University of Connecticut MD/MPH candidate 
 
 
English and French Introductory Email 
 
Docteur __________, 
 
Nous faisons une étudie pour déterminer les traitements utilisés par les médecins pour 
prévenir la fièvre rhumatismale et des cardiopathies rhumatismales. Nous avons été 
informés des pénuries dans la fourniture de Pénicilline G Benzathine (BPG), le traitement 
préventif recommandé par l’Organisation Mondiale de la Santé et d’autres organisations. 
Si vous êtes un médecin qui traite des patients atteints de fièvre rhumatismale et des 
cardiopathies rhumatismales, s’il-vous plaît remplissez l’enquête, qui est attachée en 
français et en anglais. Pour une explication plus complète s'il vous plaît voir l’enquête.  
 
Cordialement, 
Stephen Marko 
Fédération Mondiale de Cardiologie 
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Dr. __________, 
 
You are being contacted because we, at the World Heart Federation, have identified you 
as having a clinical interest in rheumatic fever or rheumatic heart disease. You have been 
chosen to participate in an important survey-based study that seeks to recognize treatment 
protocols currently in use by clinicians who perform primary or secondary prophylaxis on 
rheumatic fever or rheumatic heart disease patients. We are attempting to define and 
assess quantitative and qualitative benzathine penicillin G supply issues in global regions 
with a high burden of rheumatic fever and rheumatic heart disease. You know how 
important it is for your RHD patients to receive appropriate care and we have had reports 
of penicillin shortages and poor quality penicillin. The attached survey should take 
approximately 15-30 minutes to complete. You may be the only survey respondent in 
your country so don't let your country’s voice go unheard! Individual results will be held 
confidential and compiled results will be distributed to all survey respondents. Your 
individual participation in this survey is extremely important and the validity of the study 
depends on adequate numbers of respondents - every response counts. If you have any 
questions about the study or the validity of this email, please don't hesitate to contact me 
by hitting 'reply' or writing to Stephen.Marko@worldheart.org. I apologize for my 
rudimentary French, the survey (attached in French and English) has been translated by a 
professional service. I look forward to your reply. 
 
Thank you, 
Stephen Marko 
World Heart Federation 
 
 
English and Spanish Introductory Email 
 
Estimado Dr. __________, 
 
Estamos contactándole porque nosotros, en the World Heart Federation, le hemos 
identificado ser una persona con un interés clínico en fiebre reumática o enfermedad 
reumática del corazón (RF/RHD). Usted ha sido seleccionado para participar en un 
importante encuesta que intenta de reconocer protocolos de tratamiento utilizado por 
trabajadores de la salud que cuidan a pacientes de RF/RHD. Estamos tratando de 
definir y evaluar los temas cuantitativos y cualitativos del suministro de penicilina 
benzatina G (BPG) en regiones del mundo con alta incidencia de RF/RHD. Usted 
sabe que es importante para sus pacientes tener cuida adecuada y hemos tenido reportes 
de escasez de la penicilina y tambien penicilina de mala calidad. La 
encuesta adjunta deberá durar aproximadamente 15-30 minutos. Es posible que usted será 
el demandado sólo en su país, ¡no deje que la voz de su gente falta! Su participación 
individual en esta encuesta es de suma importancia y la validez del estudio depende de un 
número suficiente de participantes - cada respuesta es importante. Si usted tiene alguna 
pregunta sobre el estudio o la validez de este correo electrónico, por favor no dude 
en ponerse en contacto conmigo por escribiendo a Stephen.Marko@worldheart.org. Lo 
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siento por mi Español rudimentario, la encusta (adjuntado en Español y Inglés) ha sido 
traducido por un servicio profesional. Espero su respuesta. 
Muchas gracias, 
Stephen Marko 
World Heart Federation 
Universidad de Connecticut MD/MPH Candidato 
 
Dear Dr. __________, 
 
You are being contacted because we, at the World Heart Federation, have identified you 
as having a clinical interest in rheumatic fever or rheumatic heart disease. You have been 
chosen to participate in an important survey-based study that seeks to recognize treatment 
protocols currently in use by clinicians who perform primary or secondary prophylaxis on 
rheumatic fever or rheumatic heart disease patients. We are attempting to define and 
assess quantitative and qualitative benzathine penicillin G supply issues in global regions 
with a high burden of rheumatic fever and rheumatic heart disease. You know how 
important it is for your RHD patients to receive appropriate care and we have had reports 
of penicillin shortages and poor quality penicillin. The attached survey should take 
approximately 15-30 minutes to complete. You may be the only survey respondent in 
your country so don't let your country’s voice go unheard! Individual results will be held 
confidential and compiled results will be distributed to all survey respondents. Your 
individual participation in this survey is extremely important and the validity of the study 
depends on adequate numbers of respondents - every response counts. If you have any 
questions about the study or the validity of this email, please don't hesitate to contact me 
by hitting 'reply' or writing to Stephen.Marko@worldheart.org. I apologize for my 
rudimentary Spanish, the survey (attached in Spanish and English) has been translated by 
a professional service. I look forward to your reply. 
 
Thank you, 
Stephen Marko 
World Heart Federation 
University of Connecticut MD/MPH candidate 
 
 
English Follow-Up Email 
 
Dear Dr. __________, 
 
A short time ago, I emailed you the attached survey regarding benzathine penicillin G 
supply. I have not received your completed survey and we are lacking information on 
benzathine penicillin G supply in your country. If you are qualified to complete the 
survey, it is extremely important that we learn what supply issues you are having, if any 
at all. If you are not having supply issues, it is important that we know that as well! As 
before, we have chosen you to participate in a survey-based study that seeks to define and 
assess quantitative and qualitative benzathine penicillin G supply issues in global regions 
with a high burden of rheumatic fever and rheumatic heart disease. The attached survey 
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should take approximately 15-30 minutes to complete. You may be the only survey 
respondent in your country so don't let your country’s voice go unheard! Individual 
results will be held confidential and compiled results will be distributed to all survey 
respondents. Your individual participation in this survey is extremely important and the 
validity of the study depends on adequate numbers of respondents - every response 
counts. If you have any questions about the study or the validity of this email, please 
don't hesitate to contact me by hitting 'reply' or writing to 
Stephen.Marko@worldheart.org. You may also call me at +1 802-324-5803 (please note 
that my time zone is GMT minus five hours). I look forward to your reply. 
 
Thank you again, 
Stephen Marko 
World Heart Federation 
University of Connecticut MD/MPH candidate 
 
 
Surveys 
 
Please see the next page for surveys provided in English, Spanish, and French. 
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Rheumatic Fever and Rheumatic Heart Disease Prevention 
 
ABOUT THIS STUDY: 
• The principal investigator of this study is Stephen Marko, a Doctor of Medicine and 
Master in Public Health candidate at the University of Connecticut working in 
collaboration with the World Heart Federation 
• The purpose of this study is to define and assess quantitative and qualitative benzathine 
penicillin G (BPG) supply issues in global regions with a high burden of rheumatic fever 
(RF) and rheumatic heart disease (RHD) 
• This survey is being sent to healthcare practitioners in selected countries throughout the 
world 
• Survey participants should be healthcare practitioners who perform primary or secondary 
prophylaxis treatment on RF/RHD patients 
• Survey participants should have ready access to the current stock of BPG used at their 
clinical site, if applicable 
• This survey should take approximately 15-30 minutes to complete 
• Your participation in this survey is voluntary and you may skip any question 
• You may be the only survey respondent in your country – don’t let your country’s voice 
go unheard! 
• Answers should be provided to the best of your ability 
• Completion and return of the survey implies consent to use the information it contains 
• Individual results will be held confidential 
• Compiled results will be distributed to all survey respondents 
• The results of the study will be used in the production of Mr. Marko’s Master’s thesis 
• Questions can be addressed to Mr. Marko at Stephen.Marko@worldheart.org 
 
INSTRUCTIONS: 
• Click X with the computer mouse to select a box   
• Type into each field and the spaces will expand automatically 
• Press SAVE each time the form is closed 
• Please answer as completely as possible, more information is better than less 
• Please FORWARD COMPLETED QUESTIONNAIRE to:  
Stephen.Marko@worldheart.org 
 
Your Country: 
      
Your Name: 
      
Your Designation/Title: 
      
Your Organization: 
      
Practice setting (e.g. urban/rural, 
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clinic/hospital, etc.): 
Date questionnaire completed: 
      
Please provide the name and contact information of the person we should communicate 
with in the future about BPG at your institution (e.g. yourself, another clinician, pharmacy 
representative): 
Name: 
      
Organization/Address: 
      
Phone number (+country code): 
      
     Facsimile number (+country code): 
      
Email address: 
      
         
1. Concerning the most commonly used current brand of BPG that is used at your 
institution for primary and/or secondary prophylaxis of RF/RHD [information 
available on vials/packaging]: 
Brand name: 
      
Manufacturer: 
      
Country where manufactured: 
      
Supplier: 
      
Expiration date: 
      
Preparation 
(e.g. pre-filled syringe, powder, etc.): 
 
      
If powder form, volume used for 
reconstitution (mLs): 
 
      
Type of diluent 
(e.g. sterile water, lignocaine, etc.): 
 
      
     Available dose formulations  
(e.g.1.2 million units, 2.4 million units): 
 
      
Types of BPG formulations 
(e.g. mixed with aqueous penicillin, 
procaine penicillin, or other preparations): 
 
 
      
Comments regarding formulations: 
Check this box if your institution            
does not have access to BPG: 
 
      
 
 
2. Concerning the quantity of BPG available to your institution: 
a) Please estimate how many patients your institution currently has that require secondary 
prophylaxis for RF/RHD using BPG:       
b) Given your BPG supply, please estimate how many patients your institution currently is 
capable of treating with secondary prophylaxis for RF/RHD:       
c) Has your institution experienced any problems maintaining a BPG supply adequate for 
RF/RHD primary and/or secondary prophylaxis?      
 No 
 Yes: How recently?       
d) Is there more than one brand of BPG currently used by your institution? 
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 No 
 Yes: Please list all currently used brands:       
e) Has there been a brand change of BPG in the past 2 years? 
 No 
 Yes: 
i. If yes, please list all other known brands have been used in the past 2 years: 
      
ii. If yes, have there been changes in any of the following characteristics of BPG 
(check all that apply): 
 Preparation 
 Reconstitution volume 
 Type of diluent 
 Dose formulation 
 Type of formulation 
 Other:       
iii. If yes, what were the reasons for changing? (check all that apply): 
 It was determined by an external organization 
 Availability on the market 
 Affordability 
 Quality 
 Packaging 
 Storage requirements 
 Other:       
f) Is the supply of BPG dependent upon an external organization? (e.g. an NGO, UNICEF, 
etc.)      
 No 
 Yes. Please state the name of the organization that sources BPG for your institution: 
      
g) What factors influence the decision regarding the choice of the brand of BPG used in 
your institution? (check all that apply): 
 It is determined by an external organization 
 Availability on the market 
 Affordability 
 Quality 
 Packaging 
 Storage requirements 
 Other:       
h) Does your institution have antibiotic alternatives in the event that the BPG supply is not 
adequate?     
 No  
 Yes:  
 Oral penicillin 
 Aminopenicillins (e.g. Amoxicillin, amoxicillin-clavulanate, etc.) 
 Cephalosporins (e.g. cefdinir, cefpodoxime, cephalothin, etc.) 
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 Macrolides (e.g. azithromycin, erythromycin, etc.) 
 Lincosamides (e.g. clindamycin, etc.) 
 Sulfonamides 
 Other:       
i) Please state any general comments on the quantity of BPG your institution is able to 
acquire:       
 
3. Concerning the quality of the BPG supply at your institution: 
a) How would you rate the quality of the current BPG supply? 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor 
b) Have you experienced difficulty reconstituting particular batches of BPG? 
 No 
 Yes. Please state the brand in use at the time:       
c) Have you experienced difficulty drawing reconstituted BPG into syringes? 
 No 
 Yes. Please state the brand in use at the time:       
d) Has there been evidence of breakthrough rheumatic fever with particular BPG batches? 
 No 
 Yes. Please state the brand in use at the time:       
e) Is rash a common side effect of the current BPG formulation in use at your clinical site? 
 No 
 Yes. Please state the estimated incidence of rash due to BPG:       
f) Have any of your patients experienced anaphylaxis after receiving a BPG injection? 
 No 
 Yes 
i. If yes, please state the brand in use at the time:       
ii. If yes, how has this affected the way secondary prophylaxis is performed?       
g) Have any of your patients died from anaphylaxis following a BPG injection? 
 No 
 Yes 
i. If yes, please state the brand in use at the time:       
ii. If yes, how has this affected the way secondary prophylaxis is performed?       
h) Do you inject BPG beyond the expiration date? 
 No 
 Yes 
i) Is skin testing for penicillin allergy performed at your site? 
 No 
 Yes 
i. If yes, what percentage of patients are you able to test before initiating treatment? 
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j) Please state any general comments on the quality of BPG your institution is able to 
acquire:       
 
4. Concerning national and international guidelines on RF/RHD prophylaxis: 
a) Is there any structured national program for RF/RHD prevention and control in your 
country?            
 No 
 Don’t know  
 Yes 
b) Does your country have a national RF/RHD registry? 
 No 
 Don’t know  
 Yes 
i. If yes, does your organization report into it? 
 No 
 Yes 
c) What RF/RHD prevention guidelines are currently used by your organization? 
 None 
 World Health Organization 
 American Heart Association 
 World Heart Federation                    
 India                       
 Australia and New Zealand  
 Other; please provide the name of the guidelines here:       
d) For patients at low risk of recurrent RF, how frequently do you provide prophylaxis? 
      
e) For patients at high risk of recurrent RF or patients who have had breakthrough RF on 4 
week prophylaxis, how frequently do you provide prophylaxis?       
f) If no schedule is followed, or another schedule is followed, please explain:       
g) For adults and children weighing 30kg or more, how many units of BPG are injected, if 
applicable?       
h) For children weighing less than 30kg, how many units of BPG are injected, if applicable? 
      
 
5. Concerning additional healthcare providers who treat RF/RHD: 
a) Please provide names and contact details for any other individuals or organizations which 
you feel might have additional information pertinent to this questionnaire: 
      
 
Thank you for your interest and participation 
Please forward the completed questionnaire to:  Stephen.Marko@worldheart.org 
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La Prevención de Fiebre Reumática y 
Enfermedad Reumática del Corazón  
 
SOBRE ESTE ESTUDIO: 
• El investigador principal de este estudio es Stephen Marko, estudiante para Doctor en 
Medicina y Master en Salud Pública en la Universidad de Connecticut que trabaja en 
colaboración con la Federación Mundial de Cardiología 
• El propósito de este estudio es definir y evaluar los temas cuantitativos y cualitativos del 
suministro de penicilina G benzatina (BPG) en regiones del mundo con alta incidencia de 
fiebre reumática (RF) y enfermedad reumática del corazón (RHD) 
• Esta encuesta está siendo enviada a médicos en países de todo el mundo 
• Los participantes de la encuesta deben ser médicos que tienen pacientes de RF/RHD 
• Los participantes de la encuesta deben tener fácil acceso a las existencias de BPG en uso 
en su clínica, si la clínica tiene acceso a BPG  
• Completar este instrumento de la encuesta no debe llevar más de 15-30 minutos  
• Su participación en esta encuesta es voluntaria y se puede dejar de contestar cualquiera de 
las preguntas  
• Podría ser el único en su país que esté respondiendo a esta encuesta – ¡no deje que la voz 
de su país no sea escuchada! 
• Las respuestas deben contestarse lo mejor que se pueda 
• Completar y devolver este cuestionario implica consentimiento para que la información 
que contiene sea usada 
• Resultados individuales estará dejado confidencial 
• Un compilado de los resultados les será enviado a todos los que hayan respondido a la 
encuesta 
• Los resultados del estudio serán utilizados en la producción de la tesis de Master del Sr. 
Marko 
• En caso de preguntas, pueden ser enviadas al Sr. Marko a 
Stephen.Marko@worldheart.org 
 
INSTRUCCIONES: 
• Marque X con el mouse del ordenador para seleccionar un casillero   
• Escriba en cada campo y los espacios se expandirán automáticamente 
• Marque GUARDAR cada vez que cierre el formulario 
• Por favor responda lo más completamente posible, es mejor que haya información 
de más y no de menos  
• Por favor REENVÍE EL CUESTIONARIO COMPLETADO a:  
Stephen.Marko@worldheart.org 
 
Su País: 
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Su Nombre: 
      
Su Designación/Título: 
      
Su Organización: 
      
Ubicación del consultorio (por ej. 
urbano/rural, clínica/hospital, etc.):       
Fecha en la que completó el cuestionario: 
      
 
Por favor indique el nombre y la información de contacto de la persona con la que debemos 
comunicarnos a futuro sobre BPG en su institución (por ej. usted, o un clínico / 
representante farmacéutico): 
Nombre: 
      
Organización/Dirección: 
      
Teléfono (+código país): 
      
     Facsímil (+código país): 
      
Dirección email: 
      
         
6. Referente a la marca actualmente más comúnmente en uso de BPG en su institución 
para profilaxis primaria y/o secundaria de RF/RHD [información disponible en las 
ampollas/embalajes actualmente en uso]: 
Marca: 
      
Fabricante: 
      
País del fabricante: 
      
Proveedor: 
      
Fecha de vencimiento/caducidad: 
      
Preparación 
(por ej. jeringa pre-cargada, polvo, etc.):       
Si es en polvo, volumen que se usa para 
reconstituir (mLs):       
Tipo de diluyente 
(por ej. agua esterilizada, lignocaína, etc.):       
     Formulaciones de dosis disponibles  
(por ej. 1,2 millones de unidades, 2,4 
millones de unidades): 
      
Tipos de formulaciones BPG 
(por ej. combinada con penicilina acuosa, 
penicilina procaína, u otras preparaciones): 
      
Comentarios referentes a las formulaciones: 
Marque X con el mouse del ordenador si su 
institución no tiene acceso a BPG: 
 
      
 
 
 
7. Referente a la cantidad de BPG disponible en su institución: 
k) Por favor estime cuantos pacientes su organización tiene actualmente que requieran 
profilaxis secundaria para RF/RHD  que estén usando BPG:       
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l) Dada sus existencias de BPG, por favor estime cuantos pacientes su organización es 
actualmente capaz de tratar con profilaxis secundaria para RF/RHD:       
m) ¿Su institución ha experimentado algún problema en mantener existencias suficientes de 
BPG para profilaxis primaria y/o secundaria de RF/RHD?      
 No 
 Sí: ¿Hace cuánto tiempo?       
n) ¿Hay más de una marca de BPG actualmente en uso en su organización? 
 No 
 Sí: Por favor liste todas las marcas en uso actualmente:       
o) ¿Han cambiado de marca de BPG en los últimos 2 años? 
 No 
 Sí: 
i. Si respondió sí, por favor liste todas las demás marcas conocidas utilizadas en los 
últimos 2 años:       
ii. Si respondió sí, ¿han habido cambios en cualquiera de las siguientes 
características de BPG? (marque todas las que correspondan): 
 Preparación 
 Volumen de reconstitución 
 Tipo de diluyente 
 Formulación de dosis 
 Tipo de formulación 
 Otros:       
iii. Si respondió sí, ¿cuáles fueron los motivos del cambio? (marque todos los que 
correspondan): 
 Fue decidido por una organización externa 
 Disponibilidad en el mercado 
 Asequibilidad en costo 
 Calidad 
 Embalaje 
 Requisitos de almacenamiento 
 Otros:       
p) ¿Las existencias de BPG dependen de una organización externa? (por ej. una ONG, 
UNICEF, etc.)      
 No 
 Sí. Por favor indique el nombre de la organización que le proporciona BPG a su 
institución:       
q) ¿Qué factores influyen en la decisión referente a la elección de la marca de BPG que 
utiliza su institución? (marque todos los que correspondan): 
 Es decidido por una organización externa 
 Disponibilidad en el mercado 
 Asequibilidad en costo 
 Calidad 
 Embalaje 
 Requisitos de almacenamiento 
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 Otros:       
r) ¿Su institución tiene alternativas de antibióticos si las existencias de BPG no fueran 
suficientes?     
 No  
 Sí:  
 Penicilina oral 
 Aminopenicilinas (por ej. Amoxicilina, amoxicilina-clavulanato, etc.) 
 Cefalosporinas (por ej. cefdinir, cefpodoxima, cefalotina, etc.) 
 Macrólidos (por ej. azitromicina, eritromicina, etc.) 
 Lincosamidas (por ej. clindamicina, etc.) 
 Sulfonamidas 
 Otros:       
s) Por favor realice comentarios generales sobre la cantidad de BPG que su institución 
puede adquirir:       
 
8. Referente a la calidad de las existencias de BPG en su institución: 
j) ¿Cómo calificaría la calidad de la existencia actual de BPG? 
 Excelente 
 Muy buena 
 Buena 
 Regular 
 Mala 
k) ¿Ha experimentado alguna dificultad al reconstituir algún lote en especial de BPG? 
 No 
 Sí. Por favor diga qué marca estaban usando en ese momento:       
l) ¿Ha experimentado alguna dificultad al llenar la jeringa con BPG reconstituido? 
 No 
 Sí. Por favor diga qué marca estaban usando en ese momento:       
m) ¿Ha habido evidencia de irrupción de fiebre reumática con algún lote en especial de 
BPG? 
 No 
 Sí. Por favor diga qué marca estaban usando en ese momento:       
n) ¿Es común en su clínica que se produzca una erupción como efecto colateral con la 
formulación de BPG que se usa actualmente? 
 No 
 Sí. Por favor estime la incidencia de erupciones debido al uso de BPG:       
o) ¿Alguno de sus pacientes han experimentado anafilaxis luego de ser inyectados con 
BPG? 
 No 
 Sí 
i. Si respondió sí, por favor diga qué marca estaban usando en ese momento:       
ii. Si respondió sí, ¿cómo afectó esto el modo en el que se lleva a cabo la profilaxis 
secundaria?       
p) ¿Alguno de sus pacientes ha fallecido de anafilaxis luego de ser inyectado con BPG? 
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 No 
 Sí 
i. Si respondió sí, por favor diga qué marca estaban usando en ese momento:       
ii. Si respondió sí, ¿cómo afectó esto el modo en el que se lleva a cabo la profilaxis 
secundaria?       
q) ¿Inyecta BPG después de su fecha de vencimiento? 
 No 
 Sí 
r) ¿Se realizan pruebas cutáneas de alergia a la penicilina en su clínica? 
 No 
 Sí 
ii. Si respondió sí, ¿cuál es el porcentaje de pacientes que pueden testear antes de 
iniciar tratamiento?       
t) Por favor realice cualquier comentario general sobre la calidad del BPG que su 
institución puede adquirir:       
 
9. Referente a directivas nacionales e internacionales sobre profilaxis de RF/RHD: 
i) ¿Hay algún programa nacional estructurado de prevención y control de RF/RHD en su 
país?            
 No 
 No sé  
 Sí 
j) ¿Su país tiene un registro nacional de RF/RHD? 
 No 
 No sé  
 Sí 
i. Si respondió sí, ¿su organización le informa al mismo? 
 No 
 Sí 
k) ¿Qué directivas de prevención de RF/RHD están siendo utilizadas actualmente por su 
organización? 
 Ninguna 
 Organización Mundial de la Salud 
 American Heart Association [Asociación Americana de Cardiología] 
 World Heart Federation [Federación Mundial de Cardiología]                    
 India                       
 Australia y Nueva Zelanda  
 Otros; por favor indique a continuación el nombre de las directivas:       
l) Para pacientes con bajo riesgo de recurrencia de RF, ¿con qué frecuencia les proporciona 
profilaxis?       
m) Para pacientes con alto riesgo de recurrencia de RF o pacientes para los que hubo una 
irrupción de RF en una profilaxis de 4 semanas, ¿con qué frecuencia se les proporciona 
profilaxis?       
n) Si no se programa la profilaxis, o se programa de otro modo, por favor explíquelo:       
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o) Para adultos y niños que pesan 30 kilos o más, ¿cuántas unidades de BPG están 
inyectado, si aplicable?       
p) Para niños que pesan menos de 30 kilos, ¿cuántas unidades de BPG están inyectado, si 
aplicable?        
 
10. Referente a proveedores de asistencia a la salud que tratan RF/RHD: 
• Por favor proporcione el nombre y los detalles de contacto para cualquier otro 
individuo u organización que usted considere podría tener información adicional 
pertinente a este cuestionario: 
      
 
Muchas gracias por su interés y participación 
Por favor reenvíe el cuestionario completado a: Stephen.Marko@worldheart.org. 
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et des Cardiopathies Rhumatismales 
 
A PROPOS DE CETTE ÉTUDE: 
 
• Le principal instigateur de cette étude est Stephen Marko, Docteur en Médecine et 
étudiant en Master en Santé Publique à l’Université du Connecticut, qui travaille en 
collaboration avec la World Heart Federation (Fédération Mondiale de Cardiologie). 
• Le but de cette étude est de préciser et d’évaluer, quantitativement et qualitativement, 
l’administration de Pénicilline G Benzathine (BPG) dans les régions du monde présentant 
un taux élevé de cas de fièvre rhumatismale et de cardiopathies rhumatismales.  
• Cette enquête est envoyée à des praticiens de santé dans divers pays à travers le monde 
• Les participants à cette enquête doivent être des praticiens de santé qui traitent des 
patients atteints de RF/RHD (fièvre rhumatismale et cardiopathies rhumatismales) 
• Les participants à l’enquête doivent avoir libre accès au stock de BPG du centre de soins 
où ils exercent, si la clinique utilise de la BPG pour prévenir les RF/RHD 
• Remplir ce formulaire d’enquête ne devrait pas prendre plus de 30 mn 
• La participation à cette enquête est facultative et il n’est pas obligatoire de répondre à 
toutes les questions 
• Peut-être serez-vous le seul praticien de votre pays à répondre à cette enquête – Ne 
permettez pas que la voix de votre pays reste muette 
• Répondez aux questions posées au meilleur de vos compétences 
• Remplir ce formulaire d’enquête et le retourner implique votre consentement à ce que les 
informations qu’il contient soient utilisées 
• Les résultats individuels seront confidentiels 
• Une compilation des résultats de l’enquête sera communiquée à tous ceux qui y ont 
participé 
• Les conclusions de l’étude seront utilisées pour la rédaction de la thèse de M. Marko 
• Toute question peut être adressée à M. Marko par courriel à 
Stephen.Marko@worldheart.com 
 
INSTRUCTIONS: 
• Taper X avec la souris de l’ordinateur dans la case que vous avez choisie   
• Ecrivez dans chaque champ, celui-ci s’agrandira automatiquement 
• ENREGISTRER le formulaire à chaque fois que vous fermez le document 
• Merci de donner les informations les plus complètes possibles. Trop 
d’informations valent mieux que pas assez 
• Merci de TRANSMETTRE LE QUESTIONNAIRE DÛMENT REMPLI à: 
Stephen.Marko@worldheart.org 
Votre Pays: 
      
Votre Nom: 
      
Votre Dénomination/Titre: 
      
Votre Organisation: 
      
Milieu dans lequel vous exercez (ex. urbain/rural, 
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clinique/hôpital, etc.): 
Date à laquelle vous avez rempli le questionnaire: 
      
 
Merci de préciser le nom et les informations de contact de la personne à laquelle nous 
devons nous adresser à l’avenir au sujet de la BPG au sein de votre institution (ex. vous-
même, ou un clinicien/ pharmacien responsable) 
Nom: 
      
Organisation/Adresse: 
      
N° de Tél (+code du pays): 
      
     N° de Fax (+code du pays): 
      
 Adresse Email: 
      
         
11. A propos de la marque de BPG actuellement la plus utilisée dans votre institution pour 
la prophylaxie primaire et secondaire des RF/RHD (information fournie sur les 
flacons/les emballages courants): 
Marque: 
      
Fabricant: 
      
Adresse du fabricant: 
      
Fournisseur: 
      
Date de péremption: 
      
Conditionnement 
(ex. seringue pré-remplie, poudre, etc.):       
S’il s’agit de poudre, volume utilisé pour la 
reconstitution (ml)       
Type de diluant 
(ex. eau stérile, lignocaïne, etc.):       
     Formulation des doses disponibles 
    (ex.1.2 millions d’unités, 2.4 millions d’unités):       
Types de formulation 
(ex. combinée avec de la pénicilline aqueuse, de la 
pénicilline procaïne, ou d’autres préparations): 
      
Commentaires sur les formulations: 
Taper X avec la souris de l’ordinateur dans la 
case si votre institution n’a pas accès à la BPG: 
 
      
 
 
 
12. A propos de la quantité de BPG disponible dans votre institution: 
u) Merci de donner une estimation du nombre de patients actuellement soignés dans votre 
institution qui requièrent une prophylaxie secondaire à la BPG pour une RF/RHD :       
v) Tenant compte de votre approvisionnement en BPG, merci d’estimer le nombre de 
patients que votre institution est actuellement en mesure de traiter à la BPG avec une 
prophylaxie secondaire pour une RF/RHD       
w) Votre institution a-t-elle rencontré des problèmes pour assurer un approvisionnement 
suffisant en BPG pour la prophylaxie primaire ou secondaire des RF/RHD ?   
 Non 
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 Oui   Il y a combien de temps ?       
x)  Votre institution utilise-t-elle actuellement plus d’une marque de BPG? 
 Non 
 Oui: Merci de citer toutes les marques actuellement utilisées:       
y) Y a-t-il eu un changement de marque de BPG au cours des deux dernières années? 
 Non 
 Oui: 
i. Si oui, citez le nom de toutes les autres marques connues utilisées au cours des 
deux dernières années:       
ii. Si oui, y a-t-il eu des changements parmi les caractéristiques suivantes de la BPG 
(cocher tout ce qui convient): 
 Préparation 
 Volume de reconstitution  
 Type de diluant 
 Formulation de la dose 
 Type de formulation 
 Autre:       
iii. Si oui, quelles étaient les raisons de ce changement? (cocher tout ce qui 
convient): 
 Cela a été décidé par une organisation externe 
 Disponibilité sur le marché 
 Accessibilité du prix 
 Qualité 
 Conditionnement 
 Impératifs de stockage 
 Autre:       
z) L’approvisionnement en BPG dépend-il d’une organisation externe ? (ex. une ONG, 
l’UNICEF, etc.)     
 Non 
 Oui. Merci de citer le nom de l’organisation qui fournit votre institution en BPG: 
      
aa) Quels sont les facteurs qui influencent la décision du choix de la marque de BPG utilisée 
par votre institution? (cocher tout ce qui convient): 
 Il est déterminé par une organisation externe 
 Disponibilité sur le marché 
 Accessibilité du prix 
 Qualité 
 Conditionnement 
 Impératifs de stockage 
 Autre:       
bb) Votre institution a-t-elle des alternatives en antibiotiques en cas d’insuffisance de stock 
en BPG?    
 Non  
 Oui:  
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 Pénicilline orale 
 Aminopénicillines (ex., Amoxicilline-clavulanate, etc.) 
 Céphalosporines (ex. cefdinir, cefpodoxime, cephalothin, etc.) 
 Macrolides (ex. azithromycine, érythromycine, etc.) 
 Lincosamides (ex. clindamycine, etc.) 
 Sulfamidés 
 Autre:       
cc) Merci de faire tout commentaire sur la quantité de BPG que votre institution peut 
acquérir:       
 
13. A propos de la qualité du stock en BPG de votre institution: 
s) Quelle mention accorderiez-vous à la qualité du stock actuel en BPG de votre institution? 
 Excellente 
 Très bonne 
 Bonne 
 Passable 
 Mauvaise 
t) Avez-vous rencontré des difficultés dans la reconstitution de certains lots de BPG? 
 Non 
 Oui. Si oui, Merci de citer la marque utilisée alors:       
u) Avez-vous rencontré des difficultés lors du remplissage de la seringue avec de la BPG 
reconstituée? 
 Non 
 Oui. Si oui, Merci de citer la marque utilisée alors:       
v) Avez-vous constaté une rechute évidente de fièvre rhumatismale avec certains lots de 
BPG? 
 Non 
 Oui. Si oui, Merci de citer la marque utilisée alors:       
w) La formulation de BPG actuellement utilisée dans le centre de soins où vous exercez a-t-
elle pour effet secondaire courant une éruption cutanée ? 
 Non 
 Oui. Veuillez préciser l’incidence des éruptions cutanées que vous attribuez à l’usage 
de BPG       
x) L’un de vos patients a-t-il été victime d’une réaction anaphylactique suite à une piqûre de 
BPG?  
 Non 
 Oui 
i. Si oui, Merci de citer la marque utilisée alors:       
ii. Si oui, en quoi cela a-t-il affecté la procédure de prophylaxie secondaire?       
y) L’un de vos patients est-il décédé d’anaphylaxie, suite à une piqûre de BPG? 
 Non 
 Oui 
i. Si oui, Merci de citer la marque utilisée alors:       
ii. Si oui, en quoi cela a-t-il affecté la procédure de prophylaxie secondaire?       
 65 
z) Injectez-vous la BPG après sa date de péremption ? 
 Non 
 Oui 
aa) Pratique-t-on des tests cutanés d’allergie à la pénicilline dans votre clinique ?  
 Non 
 Oui 
i. Si oui, quel est le pourcentage de patients que vous pouvez tester avant de commencer 
le traitement ?       
j) Merci de faire tout commentaire sur la qualité de BPG que votre institution peut acquérir: 
      
 
4. A propos des directives nationales et internationales sur la prophylaxie RF/RHD: 
q) Existe-t-il un programme national structuré pour la prévention et le contrôle des RF/RHD 
dans votre pays ?   
 Non 
 Je ne sais pas 
 Oui 
r) Existe-t-il dans votre pays un registre national des RF/RHD? 
 Non 
 Je ne sais pas  
 Oui 
i. Si oui, votre organisation en reporte-t-elle à lui ? 
 Non 
 Oui 
s) Quelles sont les directives en matière de prévention des RF/RHD qu’applique 
aujourd’hui votre organisation? 
 Aucune 
 Organisation Mondiale de la Santé 
 American Heart Association (Association Américaine de Cardiologie) 
 World Heart Federation  (Fédération Mondiale de Cardiologie)                  
 Inde                   
 Australie et Nouvelle-Zélande 
 Autre; Merci d’indiquer ci-après le nom des directives :       
t) Pour les patients à faible risque de récurrence de RF, à quelle fréquence leur dispensez-
vous un traitement prophylactique ?        
u) Pour les patients à haut risque de récurrence de RF, ou pour les patients qui ont rechuté 
dans les 4 semaines suivant le traitement prophylactique, à quelle fréquence leur 
dispensez-vous un traitement prophylactique ?        
v) En l’absence d’un programme, ou si un autre programme est suivi, merci d’expliquer: 
      
w) Pour les adultes et les enfants pesant 30 kg ou plus, combien d'unités de BPG sont 
injectés, le cas échéant?       
x) Pour les enfants pesant moins de 30 kg, combien d'unités de BPG sont injectés, le cas 
échéant ?       
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5. A propos d’autres fournisseurs de produits de santé qui traitent les RF/RHD 
• Merci de transmettre les noms et les coordonnées détaillées de toute personne ou 
organisation qui pourrait, selon vous, fournir des informations pertinentes quant à 
ce questionnaire. 
      
 
Nous vous remercions de l’intérêt que vous nous portez et de votre participation à 
cette enquête. 
Nous vous prions de bien vouloir envoyer le questionnaire à 
Stephen.Marko@worldheart.org. 
 
 
 
 
 
 
 
